<DOC>
	<DOCNO>NCT00461396</DOCNO>
	<brief_summary>- The primary aim study evaluate impact titration , analgesic , 12 month telephone follow-up period B.E.T.A nurse program upon adherence treatment Betaseron patient first clinical demyelinate event suggestive Multiple Sclerosis ( MS ) patient onset RRMS within past 12 month - Secondary outcome include analysis follow parameter : progression clinical severity expand disability status scale ( EDSS score ) , health relate quality life ( HrQoL ) , safety . - Exploratory outcome include change time cytokine neurotrophic factor production immune cell visual function assess visual examination , OCT measurements neuro-ophthalmologic Health-Related Quality Life questionnaire ( NEI-VFQ-25 ) 10-item supplement .</brief_summary>
	<brief_title>Success Titration , Analgesics , B.E.T.A Nurse Support Acceptance Rates Early Multiple Sclerosis ( MS ) Treatment With Betaseron</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Have cognitive impairment may prevent patient complete questionnaire , assess examine physician screen Diagnosis early ( &lt; 1 year since onset ) RRMS , first clinical episode suggestive demyelinating disease ( explained condition ) within last 90 day prior screen Presence least 2 typical MS lesion brain MRI Kurtzke Expanded Disability Status Scale ( EDSS ) score 0 4.0 Willing enroll MS Pathways support program agree train , followup phone call , B.E.T.A . nurse Any disease multiple sclerosis would better explain patient 's neurological sign symptom Complete transverse myelitis simultaneous onset optic neuritis Diagnosis Primary progressive MS , secondary Progressive MS , relapse progressive MS diagnosis relapse remit MS great 12 month Clinically significant heart disease uncontrolled cardiac dysrhythmias , uncontrolled angina pectoris , cardiomyopathy , uncontrolled heart failure History severe , uncontrolled , untreated depression , attempt suicide suicidal ideation Uncontrolled seizure disorder History hypergammaglobulinemia Known hypersensitivity IFNB1b human proteins include albumin Known allergy GadoliniumDTPA document prior study entry Known general hypersensitivity analgesic / antiinflammatory agent ( NSAIDs ) Participation MS clinical study within past six month Pretreatment follow substance prior study enrollment within say time period : At time : IFN , glatiramer acetate ( Copaxone ) , total lymphoid irradiation , antilymphocyte monoclonal antibody treatment ( i.e . antiCD4 , antiCD52 ( alemtuzumab ) , antiVLA4 ( natalizumab ) , mitoxantrone , cyclophosphamide , azathioprine , IVIG , cyclosporine A , methotrexate , immunomodulating immunosuppressive agent include recombinant nonrecombinant cytokine 3 month prior study entry : treatment know used putative experimental MS treatment . Any presume immunomodulating agent ( e.g . statin ) describe protocol History alcohol substance abuse ( within past 5 year ) Inability unwillingness administer subcutaneous injection either self caregiver Clinically significant hepatic , renal , bone marrow dysfunction define follow laboratory evaluation : Hepatic dysfunction : AST ( SGOT ) &gt; 3x upper limit normal total bilirubin &gt; 2x upper limit normal Renal dysfunction : creatinine &gt; 1.8 mg/dl Bone marrow dysfunction : Hb &lt; 8.5 g/dl , WBC &lt; 2.5x10^9/L , platelet count &lt; 125x10^9/L Patients participate exploratory substudy exclude meet following : Known history chronic glaucoma , ocular hypertension , ischemic optic neuropathy , temporal arteritis , pseudopapilledema , retinitis pigmentosa , traumatic optic neuropathy , toxic optic neuropathy , pernicious anemia , Leber 's hereditary optic neuritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Relapsing-Remitting Multiple Sclerosis</keyword>
	<keyword>First demyelinate event</keyword>
	<keyword>MRI feature consistent MS</keyword>
</DOC>